Jan 16, 2024
Pleco Therapeutics receives FDA Orphan Drug Designation

Nijmegen, The Netherlands – 16th January 2024 – The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Pleco Therapeutics......

Sep 5, 2023
Pleco Therapeutics Announces the Appointment of Dr Henno Welgemoed as Chief Medical Officer

Nijmegen, The Netherlands – 5 September 2023 – Pleco Therapeutics BV, a specialty pharmaceutical company developing novel Plecoid™ therapies designed to......

Jun 13, 2023
Pleco attended the European Hematology Association Congress

Frankfurt, Germany 

Jan 10, 2023
Welcome to Tamara Kokaz

We are welcoming our newest team member, Tamara Kokaz. Tamara joins the Pleco family as a Medical Affairs Director. 

" Joining the esteemed Pleco Therapeutics team at this crucial......

Nov 22, 2022
HMi interviews Ivo Timmermans

Read Ivo Timmermans’ interview in Healthcare Markets International to find out how Pleco has begun and how the company has raised its funds. 

Nov 16, 2022
Acute Leukaemia Advocates Network (ALAN) Sponsorship

We are pleased to announce that Pleco Therapeutics is sponsoring Acute Leukaemia Advocates Network (ALAN) to support its ongoing and future activities.

ALAN is an independent global......

Oct 26, 2022
CPHI Frankfurt

Meet Pleco’s US President at CPHI in Frankfurt between the 1st and 3rd of November.

Get in touch to organise a meeting with Michael Stalhamer and discuss Pleco's breakthrough......

Oct 18, 2022
European Lifestars Awards

We're very proud to announce that we have been shortlisted as Series A finance raise of the year in the European Lifestars Awards ...

Sep 5, 2022
Pleco Therapeutics Announces Final Close of its Series A Financing Raising €17.3m to Progress its Novel Plecoid™ Product in Acute Myeloid Leukaemia to Regulatory Filing in USA and EU

Nijmegen, The Netherlands – 6 September 2022 – Pleco Therapeutics BV, a specialty biopharmaceutical company developing novel treatments designed to detoxify the......

Jul 26, 2022
Pleco Therapeutics Announces Expansion with the Incorporation of a U.S. Subsidiary and the Appointment of Michael Stalhamer as President


Nijmegen, The Netherlands and New Jersey, U.S.A. – 26 July 2022 – Pleco Therapeutics BV, a specialty biopharmaceutical company developing novel......

Jul 6, 2022
Celebrating our 4th Anniversary

Pleco Therapeutics is celebrating its 4th anniversary today ! 

We are proud to have achieved so much in 48 months and are looking forward to many more successful years.

May 30, 2022
ASCO 2022

Meet our CEO, Ivo Timmermans, and Dan Gelvan, our Chief R&D Officer, at ASCO22 to discuss Pleco’s unconventional approach to treat cancer. Our current focus is on rare diseases such as......

Apr 21, 2022
AML World Awareness Day

Acute Myeloid Leukaemia is the most common form of Acute Leukaemia in adults. Join us in supporting patients and their families and help raise global awareness of this devastating......

Feb 4, 2022
World Cancer Day

Today, 4th of February 2022, is World Cancer Day, an opportunity to bring attention to an illness that affects so many people in the world. 
Pleco Therapeutics is......

Jan 14, 2022
Gerben de Rijk, Pleco's Chief Legal Officer, interviewed by Novio Tech Campus


One milestone after another: Pleco Therapeutics hopes to bring improved cancer treatment to market soon


Nov 26, 2021
CEO's Interview

Pleco’s CEO, Ivo Timmermans has been interviewed by the Dutch journal Biotech News and Life Sciences. 

Read the full article here:

Nov 10, 2021
Pleco Therapeutics Announces €8.7m Strategic Partnership with Hyloris to Progress its Novel Plecoid™ Agent in Acute Myeloid Leukaemia and Small Cell Lung Cancer

Nijmegen, The Netherlands – Pleco Therapeutics BV, a specialty biopharmaceutical company developing novel combination chelating agents to detoxify the......

Oct 27, 2021
The new plecotherapeutics.com is here!

We are excited to announce the release of our new website, the completion of an extensive rebranding in response to the company’s phase of growth.
The website offers our......

Mar 17, 2021
Presentation at the Global Investor Network

We will be introducing Pleco at the Global Investor Forum on 18th March 2021. Please register to join the presentation of our CEO Ivo Timmermans at the pitching session from 4.15 – 5.30 pm......

Mar 1, 2021
Pleco Therapeutics receives funding from Oost NL

Nijmegen, March 1st, 2021 – Pleco Therapeutics has been granted financial support by the ION+ Innovation fund for small and medium-sized businesses in the province of......

Jan 12, 2021
Best wishes for 2021

We hope you and your family had a pleasant Holiday season. We wish to thank you for your support during a difficult 2020 and extend our best wishes for the New Year.

At Pleco, we had to......

Oct 7, 2020
R&D activities have started

Pleco Therapeutics has initiated a sponsored research program at The University of Texas MD Anderson Cancer Center based upon intellectual property developed at MD Anderson and licensed by......

May 26, 2020
New non-executive director

Pleco is pleased to announce the appointment of Brenda Reynolds as member of its independent, non-executive board, effective 20th of May. Brenda has a background as a toxicologist and has......

Jan 24, 2020
Announcement of non-executive team

Pleco is pleased to announce the appointment of Gerard van Leijenhorst, Debra Ainge and Callum Meikle to the non-executive board of directors. Gerard, Debra and Callum are all senior executives......

Dec 4, 2019
Pleco signs license agreement with MD Anderson

Pleco Therapeutics has signed an agreement whereby Pleco licenses intellectual property developed at The University of Texas MD Anderson Cancer Center with the aim of developing innovative......

Oct 1, 2019
Pleco moves to new office at Pivot Park

Oss, 1st October 2019 – The Pleco team is pleased to announce that we have moved to our new office at Pivot Park in Oss, Noord-Brabant. The Pivot Park ecosystem consists......